Vitamin K was discovered by Henrik Dam in 1929 while studying cholesterol metabolism in chicken (see Discovery of Vitamin K and It’s Targets and Antagonists). It is a co-factor for post translation gamma carboxylation of glutamate residues on peptides. This reaction is critical for function of affected molecules. Most peptides undergoing γ-carboxylation are involved in coagulation. Antagonists of vitamin K have an anticoagulant action. Before the availability of direct thrombin inhibitors, vitamin K antagonists were the only oral drugs available to reduce thrombosis risk. Long acting vitamin K antagonists are used as rodenticide.
Absorption and Daily Requirements
Vitamin K is a generic term applied to menadione (2-methyl-1,4-naphthoquinone) and its derivatives that can correct bleeding disorder in animals fed on a vitamin K deficient diet. It is a fat soluble vitamin. Dietary vitamin K is protein bound. Proteolytic enzymes of the pancreas and small intestine digest the protein liberating vitamin K. The bile salts solubilise vitamin for absortion. The daily requirements vary with age the requirement in adults varies from 55-65 µg per day (For recommended nutritional intake of vitamin K see WHO recommendations, US recomendations, Australian recomendations, Summary of European recomendations)
Vitamin K acts as a co-factor for the γ-carboxylation of glutamate residues on prothrombin, coagulation factors VII, IX, X, protein C protein S, protein Z, osteocalcin and Gas6 (figure 1). The reaction adds another -COOH residue to the γ carbon of glutamic acid (figure 2). The reaction is catalysed by γ-glutamyl carboxylase and needs C02, O2 and vitamin K. The process results in γ-carboxylation of between 9-13 residues at the amino terminal of the listed protein. Gamma carboxylation is essential for the coagulation factors to undergo a Ca2+ dependent conformational change. The conformation change allows interaction between the coagulation factors and phospholipids present on the surface of damaged vascular endothelium and activated platelets. The vitamin K epoxide needs to be reduced to be recycled. The epoxide is reduced to vitamin K by a pair of enzymes. The first of the pair (vitamin K epoxide reductase) converts vitamin K epoxide to vitamin K and the second (NAD(P)H- dependent quinolone reductases) converts vitamin K to reduced vitamin K. (see figure above).
Mechanisms of Action of Oral Anticoagulants
Vitamin K antagonists inhibit the enzymes that reduce vitamin K depleting reduced vitamin K. γ-Carboxylation can not proceed functionally impaired vitamin K dependent factors are produced. The vitamin K antagonists inhibit procoagulants as well as inhibitors of coagulation. On a long term the anticoagulant effect dominates but early on in therapy the procoagulant effect may dominate. This is believed to be responsible for warfarin induced skin necrosis. The risk is reduced by initiating oral anticoagulant therapy under cover of warfarin.